Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 15, 2010

View Archived Issues

ATL-313 and dexamethasone have synergistic antitumor effect in models of multiple myeloma

Tasocitinib shows promising pharmacokinetics in ocular tissues

Vertex Pharmaceuticals patents new protein kinase C inhibitors

New ligands of nicotinic acetylcholine receptor alpha 7 disclosed by NeuroSearch

Treatment complete in phase II trial of fasitibant in osteoarthritis

Lilly suspends phase III trial of tasisulam in metastatic melanoma

Merck Frosst identifies potent 5-LO inhibitor MK-5286

CCX-721 has antitumor effects in murine model of multiple myeloma

Scientists identify new genetic link to risk of psoriasis

Angelica Therapeutics receives grant for anticancer candidate angeloxin

Orexo's new sublingual tablet formulation of buprenorphine/naloxone completes phase I trial

New PI3K-delta/gamma inhibitors discovered at Cellzome

Santen launches Diquas in Japan for dry eye syndrome

Bepotastine besilate nasal spray advances into phase II trial in allergic rhinitis

New inhibitors of fatty-acid amide hydrolase 1 claimed

Preliminary phase Ib/IIa data presented on ibudilast in opioid addiction

Phase II trial of EGEN-001 in advanced ovarian cancer opens enrollment

FDA approves Prezista/ritonavir q.d. for treatment-experienced adults with HIV and no DRV RAMs

Lexicon Pharma reports phase IIa data on LX-2931 in rheumatoid arthritis

New inhibitors claimed of mitochondrial cytochrome P450 11B1/2

Anaphore and Mitsubishi Tanabe Pharma to develop protein therapies for autoimmune disorders

PATH MVI, Merck & Co. and NYU Langone Medical Center to develop malaria vaccine

MHRA accepts BioMarin's application for phase III GALNS trial in MPS IVA

Neurokine completes trial plan for etanercept in Alzheimer's-type memory loss after CABG surgery

Novartis to take full ownership of Alcon

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...